Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma

NCT ID: NCT06884683

Last Updated: 2025-03-19

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-17
• Study Completion Date: 2023-09-13

Brief Summary

Phase 2 single arm study that evaluated the addition of metformin to nivolumab in pre-treated metastatic renal cell carcinoma (mRCC) patients.

Primary aim: to investigate the efficacy of the combination of nivolumab+metformin in mRCC patients previously treated with VEGFR-TKI

Secondary aims:

• to assess the activity, safety and efficacy of the experimental combination
• to assess the quality of life of enrolled patients

Enrolled patients will received:

• nivolumab 240 mg e.v. every 14 day
• metformin 500 mg orally twice a day continuously Patients will be trated untill disease progression, or unexpected toxicity, whichever comes first

Conditions

Metastatic Renal Cell Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

experimental

nivolumab plus metformin Participants will receive nivolumab 240 mg e.v. every 14 days. Treatment will continue until progressive disease or discontinuation.

Participants will receive metformin 500 mg orally twice a day. Treatment will continue until progressive disease or discontinuation.

Group Type: EXPERIMENTAL

Metformin

Intervention Type: DRUG

Drug: metformin tablet 500 mg, 1 tablet twice a day (total dose 1000 mg daily), administered orally continuously

+

Biological: Nivolumab 240 mg via IV infusion every 14 days

Other Names:

Opdivo®

Interventions

Metformin

Drug: metformin tablet 500 mg, 1 tablet twice a day (total dose 1000 mg daily), administered orally continuously

+

Biological: Nivolumab 240 mg via IV infusion every 14 days

Other Names:

Opdivo®

Intervention Type: DRUG

Other Intervention Names

Nivolumab

Eligibility Criteria

Inclusion Criteria

1. Willing and able to provide written informed consent

2. Male and female aged 18 years and above

3. Histological confirmation of RCC with a clear cell component

4. Advanced or metastatic RCC

5. Measurable disease as defined by RECIST1.1criteria

6. Must have received at least one prior systemic treatment regimen in the advanced or metastatic setting, and must have evidence of progression on or after the last treatment regimen received

7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2

8. Adequate bone marrow and chemistry values defined as:

1. Hemoglobin ≥ 9.0 g/dL independent of transfusion

2. Platelet count ≥100.000/μL

3. Serum creatinine < 1.5 x ULN or a calculated creatinine clearance ≥ 40 mL/min

4. Liver function:

i. Serum bilirubin < 1.5 x ULN (except for patients with documented Gilbert's disease) ii. AST or ALT < 2.5 x ULN

9. Life expectancy of at least 6 months

10. WOCBP must use method(s) of contraception as determined to be acceptable by the principal investigator and sponsor during the study and for 23 weeks after last study drug administration.

11. Patients who are sexually active with WOCBP must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 31 weeks after last study drug administration.

Exclusion Criteria

Patients who meet any of the following criteria will be excluded from the study:

1. Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). Any positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection

2. Any active known or suspected autoimmune disease

3. Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to the first dose of study drug. Inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease

4. Uncontrolled adrenal insufficiency

5. Evidence of active pneumonitis during screening, except for pulmonary fibrosis induced by prior thoracic irradiation

6. Dialitic patients

7. Diabetes mellitus

8. Any history of biguanide-based therapy within 1 year prior to enrollment

9. Current severe, uncontrolled systemic disease

10. Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of < 50% at baseline

11. Other malignancy with a previous diagnosis within 5 years (with the exclusions of NMIBC, CIN).

12. Prior treatment with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.

13. WOCBP who are pregnant or breastfeeding

14. Women with a positive pregnancy test at enrollment or prior to administration of study medication

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

Sponsor Role: lead

Responsible Party

TORTORA GIAMPAOLO

Professor, Director of Medical Oncology and Comprehensive Cancer Center

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Giampaolo Tortora

Role: PRINCIPAL_INVESTIGATOR

Fondazione Policlinico Universitario A. Gemelli, IRCCS

Locations

Giampaolo Tortora

Roma, , Italy

Francesca Primi

Viterbo, , Italy

Countries

Italy

Other Identifiers

3209

Identifier Type: -

Identifier Source: org_study_id